Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences EW. In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.” Edwards Lifesciences closed on Thursday at $80.27.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsDavid R. LewisMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!